Moderna, Inc. is a biotechnology company specializing in the development of transformative medicines using messenger ribonucleic acid (mRNA) technology. Its primary focus lies in creating innovative therapeutics across multiple modalities, including prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology treatments, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics, and systemic intracellular therapeutics. The company advances respiratory vaccines such as those for COVID-19, RSV, seasonal influenza, and combination vaccines, alongside latent virus vaccines for cytomegalovirus, Epstein-Barr virus, herpes simplex virus, varicella zoster virus, and HIV. It also targets enteric viruses like norovirus, public health threats including Zika, Nipah, and Mpox, bacterial diseases such as Lyme, as well as oncology therapeutics like individualized neoantigen therapies and rare disease treatments for conditions including propionic acidemia, methylmalonic acidemia, glycogen storage disease, ornithine transcarbamylase deficiency, phenylketonuria, Crigler-Najjar syndrome, and cystic fibrosis. Founded in 2010 and headquartered in Cambridge, Massachusetts, Moderna, Inc. plays a pivotal role in the biotechnology sector by pioneering mRNA-based solutions for unmet medical needs in vaccines and therapeutics.